What does life with a rare kidney disease really look like?
Marianne Silkjaer Nielsen (Founder of CompCure, Denmark) offers a powerful voice for patients and caregivers. She reflects on the long diagnostic journey, the challenges of managing rare kidney disease, and the need for better awareness, advocacy, and international registries to improve outcomes.
This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).
This series was supported by Apellis and Sobi.
What does the future of treatment for C3 Glomerulopathy (C3G) look like?
Dr. Nicole van de Kar (Radboud University Medical Center, The Netherlands) unpacks the pathophysiology of C3G, from genetic and autoantibody factors to the central role of the alternative pathway. She explores the limits of current C5 therapies and the potential of new strategies targeting C3 activation that could reshape patient care worldwide.
This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).
This series was supported by Apellis and Sobi.
How do patients with C3 Glomerulopathy (C3G) present, and why is confirming the diagnosis so complex?
Dr. David Kavanagh (National Renal Complement Therapeutics Centre, United Kingdom) walks through the diagnostic process, the shortcomings of traditional immunosuppression, and the promise of emerging therapies like alternative pathway inhibitors. He also tackles one of the toughest challenges: managing post-transplant recurrence.
This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).
This series was supported by Apellis and Sobi.
Why does it matter if a kidney disease is complement-driven or complement-associated?
Dr. Matthew Pickering (Imperial College London, United Kingdom) explains this critical distinction and why it changes how clinicians approach diagnosis and treatment. The discussion explores promising new therapies such as C3 and C5 inhibitors and how biomarkers are paving the way for precision medicine in nephrology.
This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).
This series was supported by Apellis and Sobi.
Episode 19 is the third episode in KDIGO's three-episode series on acute kidney injury (AKI), hosted by Dr. Kathleen Liu (University of California at San Francisco, United States).
In this episode, Dr. Liu and Dr. Claudio Ronco (International Renal Research Institute of San Bortolo Hospital, Italy) discuss recent advancements and best practices surrounding Extracorporeal Blood Purification within the complex scenario of multiorgan support. This thought-provoking discussion, explores:
Recent clinical trials suggesting minimal benefits of early CRRT in AKI for critically ill patients. The conversation delves into whether these findings translate to patients experiencing multiorgan failure, exploring the potential differentiating factors.
The potential of CRRT to extend beyond renal support. The discussion explores how CRRT might offer support to other vital organs in the setting of multiorgan system failure.
The role of current CRRT technology in eliminating inflammatory mediators. Dr. Ronco sheds light on the capabilities of current technology and its potential impact on the inflammatory response.
Join Dr. Liu and Dr. Ronco for an insightful exploration of extracorporeal blood purification’s evolving role in optimizing care for critically ill patients.
This episode is supported by an independent educational grant from Baxter.
Episode 18 is the second episode in KDIGO's three-episode series on acute kidney injury (AKI), hosted by Dr. Kathleen Liu (University of California at San Francisco, United States). In this episode, Dr. Liu is joined by Dr. Kianoush Kashani (Mayo Clinic, United States) to discuss the rising importance of personalized care in AKI treatment. They delve into the world of digital health, exploring how digital decision support tools can empower clinicians and improve patient outcomes.
This episode will address:
Digital Health: Dr. Kashani breaks down the concept of digital health and its applications in the context of AKI management.
The Power of Digital Tools: Discover how digital decision support systems can aid clinicians in early detection, risk stratification, and personalized treatment plans for AKI patients.
Personalized Care for AKI: Dr. Liu and Dr. Kashani explore why a one-size-fits-all approach doesn't work for AKI, and how digital tools can pave the way for individualized care.
Optimizing KRT Outcomes: Learn how digital health can improve decision-making around KRT, leading to better patient outcomes.
Tune in for this informative discussion on leveraging the power of digital health to personalize AKI care.
This episode is supported by an independent educational grant from Baxter.
This is the first episode in KDIGO's new 3-episode series on acute kidney injury (AKI), hosted by Dr. Kathleen Liu (University of California at San Francisco, United States).
In this episode, Dr. Liu is joined by Dr. Jay Koyner (University of Chicago, United States) to discuss the emerging field of persistent acute kidney injury (AKI).
They delve into the question: what exactly is persistent AKI, and how does it differ from severe AKI? Dr. Liu and Dr. Koyner explore the key factors clinicians should consider when evaluating a patient's risk of developing persistent AKI. They also highlight the latest developments in this area of nephrology research, leaving listeners with valuable insights into the diagnosis and management of persistent AKI.
Join us as we discuss:
What is persistent AKI, and how is it distinguished from severe AKI?
What clinical factors should be considered when assessing a patient's risk of persistent AKI?
What are some of the new developments in the field of persistent AKI research?
How can this knowledge be applied to improve patient care?
This episode is supported by an independent educational grant from Baxter.
Join host, Dr. Peter Lin (Canadian Heart Research Centre, Canada) and Dr. Lekha Tummalapalli (Weill Cornell Medicine, United States) as they discuss the importance of early CKD detection. This episode explores risk factors, screening for CKD, and country specific factors to take into account when screening for CKD. This episode is supported by an independent educational grant from AstraZeneca.
Show Notes:
https://kdigo.org/conferences/early-identification/
https://www.theisn.org/initiatives/ckd-early-screening-intervention/
